Anteris Technologies Global Corp. AVR
Anteris is a structural heart company dedicated to revolutionizing cardiac care by pioneering science-driven and measurable advancements to restore heart valve patients to healthy function. Our lead product, the DurAVR® THV System, was designed in collaboration with the world's leading interventional cardiologists and cardiac surgeons to treat aortic stenosis — a potentially life-threatening condition resulting from a narrowing of the aortic valve. The balloon-expandable DurAVR® THV is the first biomimetic valve, which is shaped to mimic the performance of a healthy human aortic valve and aims to replicate normal aortic blood flow. Our DurAVR® THV System consists of a single-piece, biomimetic valve made with our proprietary ADAPT® tissue-enhancing technology and deployed with our balloon expandable ComASUR® Delivery System. ADAPT® is our proprietary anti-calcification tissue shaping technology that is designed to reengineer xenograft tissue into a pure, single-piece collagen bioscaffold. Our patented ADAPT® tissue has been clinically demonstrated to be calcium free for up to 10 years post-procedure, according to Performance of the ADAPT-Treated CardioCel® Scaffold in Pediatric Patients With Congenital Cardiac Anomalies: Medium to Long-Term Outcomes, published by William Neethling et. al., and has been distributed for use in over 55,000 patients globally in other indications. Our balloon expandable ComASUR® Delivery System, which was developed in consultation with physicians, is designed to provide precise alignment with the heart's native commissures to achieve accurate placement of the DurAVR® THV. As of December 2025, more than 130 patients have been implanted with the DurAVR® THV worldwide.
Valuation FY2025 figures against the last close
Where the revenue comes from as reported in the latest 10-K
Revenue by geography
- United States
- Germany
- Australia
- Other
| Region | FY2025 |
|---|---|
| United States | $1.6M |
| Germany | $272.0K |
| Australia | $33.0K |
| Other | $0 |
As the company reported it, from the “SEGMENT REPORTING - Revenues and Long-Lived Assets by Geographical Areas (Details)” note of its latest 10-K. Every figure here has been checked against the total revenue the same filing reported. Regions are the filer's own and are not mapped onto a standard list — one company's “Americas” and another's “United States” are different areas, and making them look comparable would mean making at least one of them wrong. Slices under 1% are folded into “Other”.
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Revenue | $1.9M | $2.7M | — |
| Cost of revenue | $569.0K | $1.4M | — |
| Gross profit | $1.3M | $1.3M | — |
| R&D | $69.1M | $51.5M | — |
| SG&A | $26.1M | $28.2M | — |
| Operating income | -$93.9M | -$78.4M | — |
| Pre-tax income | -$94.2M | -$76.0M | — |
| Income tax | $0 | $0 | — |
| Net income | -$94.1M | -$76.3M | — |
| EPS, basic | -2.55 | -3.68 | — |
| EPS, diluted | -2.55 | -3.68 | — |
| Shares, diluted (wtd. avg.) | 36.9M | 20.3M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Cash and equivalents | $12.6M | $70.5M | $21.1M |
| Receivables | $32.0K | $208.0K | — |
| Inventory | $152.0K | $513.0K | — |
| Total current assets | $15.7M | $74.7M | — |
| Property, plant and equipment | $5.3M | $4.8M | — |
| Other intangibles | $65.0K | $189.0K | — |
| Total assets | $23.0M | $80.7M | — |
| Accounts payable | $11.1M | $5.9M | — |
| Total current liabilities | $21.4M | $16.6M | — |
| Total liabilities | $23.2M | $18.0M | — |
| Retained earnings | -$370.5M | -$276.4M | — |
| Total equity | -$93.0K | $62.8M | $18.9M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Operating cash flow | -$77.8M | -$61.2M | — |
| Depreciation and amortisation | $1.7M | $1.5M | — |
| Stock-based compensation | $7.8M | $6.5M | — |
| Capital expenditure | $2.0M | $2.3M | — |
| Investing cash flow | -$596.0K | -$2.3M | — |
| Financing cash flow | $20.6M | $112.8M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001140361-26-006977.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Revenue | — | $2.7M | $1.9M |
| Gross profit | — | $1.3M | $1.3M |
| Net income | — | -$76.3M | -$94.1M |
Recent filings and events
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Regulation FD disclosure Item 7.01
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Results announced Item 2.02
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Material agreement terminated An agreement that mattered has ended. Often the other half of a deal that fell through. Item 1.02
- Material agreement signed Item 1.01
- Officer or director change Item 5.02
- Results announced Item 2.02
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Material agreement signed Item 1.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 3842
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| ISRG | INTUITIVE SURGICAL INC | $159.78B | 57.5x | 20.5% |
| EW | Edwards Lifesciences Corp | $51.34B | 48.7x | 11.5% |
| STE | STERIS plc | $22.63B | 29.3x | 8.7% |
| ZBH | ZIMMER BIOMET HOLDINGS, INC. | $18.80B | 27.8x | 7.2% |
| ALGN | ALIGN TECHNOLOGY INC | $10.98B | 27.3x | 0.9% |
| MSA | MSA Safety Inc | $7.03B | 25.7x | 3.7% |
| ESTA | ESTABLISHMENT LABS HOLDINGS INC. | $1.90B | — | 27.1% |
| CDRE | Cadre Holdings, Inc. | $1.28B | 29.4x | 7.5% |